Novel beta-lactamase inhibitors: a therapeutic hope against the scourge of multidrug resistance.

Novel beta-lactamase inhibitors: a therapeutic hope against the scourge of multidrug resistance.

Watkins Richard R; Papp-Wallace Krisztina M; Drawz Sarah M; Bonomo Robert A

Frontiers in microbiology

2013

2013-12

The increasing incidence and prevalence of multi-drug resistance (MDR) among contemporary Gram-negative bacteria represents a significant threat to human health. Since their discovery, beta-lactam antibiotics have been a major component of the armamentarium against these serious pathogens. Unfortunately, a wide range of beta-lactamase enzymes have emerged that are capable of inactivating these powerful drugs. In the past 30 years, a major advancement in the battle against microbes has been the development of beta-lactamase inhibitors, which restore the efficacy of beta-lactam antibiotics (e.g., ampicillin/sulbactam, amoxicillin/clavulanate, ticarcillin/clavulanate, and piperacillin/tazobactam). Unfortunately, many newly discovered beta-lactamases are not inactivated by currently available inhibitors. Is there hope? For the first time in many years, we can anticipate the development and introduction into clinical practice of novel inhibitors. Although these inhibitors may still not be effective for all beta-lactamases, their introduction is still welcome. This review focuses on the novel beta-lactamase inhibitors that are closest to being introduced in the clinic.

antibiotic resistance; beta-lactamase inhibitors

Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).

392–392

4